Delayed hemostatic changes following cardiopulmonary bypass
- PMID: 1266888
- DOI: 10.1097/00000441-197603000-00005
Delayed hemostatic changes following cardiopulmonary bypass
Abstract
A variety of hemostatic abnormalities has been reported in patients following open-heart surgery. Since surgery itself may induce changes in the coagulation system, the analyses of postoperative coagulation assays in the bleeding patients may be extremely difficult to interpret without an understanding of the coagulation dynamics in the nonhemorrhagic postoperative patients. Thus, we studied the pattern of change in several coagulation assays performed on 36 consecutive patients before and during the first two postoperative weeks. Approximately one third of the patients has some clotting abnormality before surgery. Shortened prothrombin time (PT) and activated partial thromboplastin time (APTT) were observed within the first three postoperative days. Only following warfarin therapy (initiated on the third postoperative day) was significant prolongation of PT and APTT observed. During the 14 postoperative days, fibrinogen levels and fibrinogen degradation products progressively increased without prolongation of the thrombin time or decrease in the euglobulin clot lysis time. On the first postoperative day, the platelet count and platelet adhesiveness values were significantly less than before surgery (p less than 0.01 and p less than 0.05). Over the following two weeks, the platelet count and platelet adhesiveness returned to normal. Although there was slight lengthening of the Ivy bleeding time on the first postoperative day, this assay was never abnormal. Thus, we conclude that the following cardiopulmonary bypass there is (1) probably activation of circulating procoagulants, (2) progressive increase in fibrinogen levels, (3) activation to the fibrinolytic system, and (4) transient thrombocytopenia with a superimposed platelet defect.
Similar articles
-
On-site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery.Anesthesiology. 1994 Feb;80(2):338-51. doi: 10.1097/00000542-199402000-00014. Anesthesiology. 1994. PMID: 8311316
-
Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.Semin Thromb Hemost. 2005;31(4):426-40. doi: 10.1055/s-2005-916678. Semin Thromb Hemost. 2005. PMID: 16149021
-
Alterations of hemostasis associated with cardiopulmonary bypass.Thromb Res. 1976 Mar;8(3):285-302. doi: 10.1016/0049-3848(76)90023-2. Thromb Res. 1976. PMID: 131387 No abstract available.
-
A Snapshot of Coagulopathy After Cardiopulmonary Bypass.Clin Appl Thromb Hemost. 2016 Sep;22(6):505-11. doi: 10.1177/1076029616651146. Epub 2016 Jun 5. Clin Appl Thromb Hemost. 2016. PMID: 27268940 Review.
-
Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management.Semin Thromb Hemost. 1976 Oct;3(2):59-82. doi: 10.1055/s-0028-1086129. Semin Thromb Hemost. 1976. PMID: 798278 Review.
Cited by
-
Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.J Thromb Thrombolysis. 2009 Jan;27(1):95-104. doi: 10.1007/s11239-007-0187-5. Epub 2008 Jan 23. J Thromb Thrombolysis. 2009. PMID: 18214639 Review.
-
Tranexamic acid attenuates early post-operative systemic inflammatory response and nutritional loss and avoids reduction of fibrinogen in total hip arthroplasty within an enhanced recovery after surgery pathway.Int Orthop. 2021 Nov;45(11):2811-2818. doi: 10.1007/s00264-021-05182-3. Epub 2021 Aug 18. Int Orthop. 2021. PMID: 34409492 Clinical Trial.